About Us

Archives


Page 9«..891011




Senate Ag Dems divvying up $135B in proposed ag, nutrition spending | 2021-08-10 – Agri-Pulse

Posted: August 15, 2021 at 1:45 am


Democrats on the Senate Agriculture Committee have started meeting privately to start dividing up $135 billion in new spending that would be authorized by the partisan, fiscal 2022 budget resolution the Senate is considering.

Republicans will have no input in how the funding is allocated, since they will not support the $3.5 trillion spending and tax plan Democrats are seeking to enact, Senate Agriculture Committee Chairwoman Debbie Stabenow, D-Mich. told reporters Tuesday.

We know that there will not be Republican votes, so we'll step up and write this as Democrats, she said.

A source familiar with Democrats' plans said the Senate committee members would be coordinating with theirDemocratic counterparts in the House in writing the legislation.

The allocations that the Democrats decide on will be written into a reconciliation measure that the Democrats plan to move through Congress later.

Democrats on the Senate Finance Committee,of which Stabenow also is a member,plan to meet next week to discuss the tax increases and other revenue proposals that would be included in the reconciliation bill. The tax measures are expected to include new taxes on capital gains as well as a tariff on imported goods based on their carbon footprint.

Thebudget resolution, whichcalls for $3.5 trillion in new spending on measures to address climate change and domestic priorities, provides only basic allocations to committees, leaving it to them to write their portions of the reconciliation measure.

Stabenow declined to discuss her plans for the $135 billion. She said it would allow for a substantial investment in conservation, although she wouldnt say whether it would provide the full $50 billion in conservation program funding that she had said she was seeking.

According to a a memorandum on the resolution forDemocratic senators, the $135 billionwould be used for "conservation programs, drought and forestry programs to help reduce carbon emissions and prevent wildfires;" "rural development and rural co-op clean energy investments;"agricultural research;the Civilian Climate Corps;child nutrition; and debt relief.

Interested in more coverage and insights? Receive a free month ofAgri-Pulse West

The committees top Republican, John Boozman of Arkansas, opposes the reconciliation process even though it would provide significant new funding for the next farm bill, due in 2023.He said the reconciliation measure could tie the hands of the committee that writes the farm bill.

Youre talking about spending a massive amount of money (with) no input from Republicans, no input from the Senate Ag Committee, no hearings, he said.

The committee leaders made their comments after a brief committee meeting where the panel approved two nominees for top positions at the Agriculture Department: Robert Bonnie as undersecretary for farm production and conservation, and former Rep. Xochitl Torres Small, D-N.M., to be undersecretary for rural development.

For more news, go to Agri-Pulse.com.

Visit link:
Senate Ag Dems divvying up $135B in proposed ag, nutrition spending | 2021-08-10 - Agri-Pulse

Fruits vs. vegetables: List, nutrition, benefits, and more – Medical News Today

Posted: at 1:45 am


Fruits and vegetables are an essential part of a nutritious diet. They contain vitamins, minerals, fiber, and other nutrients.

Although they both make up the basis of a nutritious diet, fruits and vegetables have classifications based on their botanical structure. The fruits people eat are the seed-bearing structure in flowering plants, while vegetables consist of edible plant stems, leaves, and other plant components.

The Department of Agriculture recommends adults consume 1.5 to 2.5 cups of fruit per day.

In addition to fruit, they should aim to eat 2 to 4 cups of vegetables. These recommendations vary depending on a persons age, weight, and sex.

According to a 2015 study, most adults in the United States do not consume enough produce.

The survey showed that just 12.2% met the daily fruit intake, while 9.3% met the daily vegetable intake. Access is likely an issue, as only 7% of adults near or below the poverty level reported they ate the required amount of vegetables per day.

Read more to learn about the differences between fruits and vegetables, the health benefits of both, and affordable ways to consume more fruits and vegetables.

Fruits and vegetables comprise different parts of the plants from which they grow.

Fruits come from the flowering part of a plant and contain seeds. In contrast, vegetables are the edible parts of a plant, such as the leaves, stem, roots, and bulbs.

People often associate fruits with sweetness and vegetables with a savory taste. Although this is often true, botanists classify some savory produce as fruits, such as tomatoes.

Savory fruits and sweet vegetables sometimes cause confusion as to their classification. Additionally, botanists and culinary experts disagree on the classification of some fruits and vegetables, further complicating the matter.

Botanists classify fruits and vegetables based on the part of the plant that they originate. However, chefs use flavor profiles, such as sweet or savory, to decide whether something is a vegetable or a fruit.

Below are some fruits and vegetables that fit into two different categories and that people often mix up.

While the tomato is technically a fruit according to botanists many consider it a vegetable due to its savory flavor.

FoodData Central (FDC), the U.S. governments central nutrient database, classifies tomatoes as vegetables. However, a tomato grows from the plants flower and has seeds, making it a fruit.

According to the FDC, cucumbers are also vegetables.

However, cucumbers come from the flowers of the plants. They also have seeds throughout them, classifying them as fruit.

People may view rhubarb as a fruit due to its distinctive flavor and role in various baked goods.

Although the FDC also classifies it as a fruit, botanists disagree. The part of the rhubarb people eat is the stem, making it a vegetable, not a fruit.

Most people consider green beans to be vegetables, and the FDC agrees.

Regardless, green beans grow from the flower of their plant, and they contain beans, which are their seeds. This makes them a fruit.

Bell peppers have seeds inside and grow from the flower of the plant, making them a fruit. However, the FDC categorizes them as vegetables.

Regardless of their technical classification, fruits and vegetables are excellent sources of vitamins, minerals, and fiber.

Many experts say that when trying to follow a nutrient-dense diet, a person should aim to eat the rainbow. This is because colorful vegetables contain vital nutrients, and their different shades indicate different nutrient profiles. A diverse diet offers a range of vitamins and minerals, which helps people consume a nutritious diet.

For example, red and orange vegetables are high in antioxidants and carotenoids. Blue or purple vegetables are rich in anthocyanins, which have anti-inflammatory and antimicrobial properties. Meanwhile, dark, leafy greens are excellent sources of calcium, fiber, and carotenoids.

Fruits also contain various beneficial nutrients. For example, many citrus fruits such as oranges, grapefruits, and limes contain vitamin C, an antioxidant that helps the bodys tissues grow and repair themselves.

Both fruits and vegetables provide health benefits.

Humans need calcium for building and maintaining strong bones. It occurs naturally in broccoli and dark, leafy greens such as kale, bok choy, and collard greens. Oranges and dried figs also provide a substantial amount of the mineral.

Vitamin C plays an essential role in the bodys ability to heal damaged tissues.

Fruits high in this vitamin include:

Both fruits and vegetables are excellent sources of fiber. However, people need to consume produce in its complete state not in juice form to get the most fiber.

Fiber prevents blood sugar spikes by slowing the digestive process, and it also helps the digestive system function properly. Brocolli, squash, pears, and apples, among other produce, are all high in fiber.

According to a 2015 study, most adults in the U.S. do not consume enough produce. The research showed that the largest disparity in vegetable consumption was poverty. Although fruits and vegetables are a proven part of a nutritious diet, they remain expensive and inaccessible to many individuals.

People living in food deserts are at a significant disadvantage. These are areas where individuals have limited access to nutritious foods.

A nutritious diet can be difficult to achieve considering these barriers to access. However, the below strategies may help ease some of these challenges.

Some produce, such asparagus and berries, can be expensive. People looking to stretch their grocery budget can try buying more affordable options.

Although the least expensive produce varies depending on the location and season, some of the most affordable fruits and vegetables include:

Learn more about eating nutritious foods on a budget.

People living in the U.S. may be eligible for the Supplemental Nutrition Assistance Program (SNAP), a monthly benefit allowing individuals to buy fruits, vegetables, meat, bread, and more.

Low income, pregnant, nursing, or postpartum individuals (until their children are 5 years of age) are also eligible for the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). This provides them access to the nutritious foods that new mothers and young infants need.

Check the eligibility criteria for SNAP and WIC.

In addition to shopping in grocery stores, people can use their SNAP dollars at most farmers markets.

The Double Up Food Bucks program, which is currently active in 25 of the 50 states, helps individuals get more for their money at the farmers market. It matches every dollar a person spends, meaning they can get twice the produce for the same price.

Learn more about Double Up Food Bucks.

Although botanists classify fruits and vegetables by their structure and seeds, many individuals and chefs classify them by their taste. Regardless, both contain essential vitamins and minerals that are important for the body.

Some benefits of eating fruits and vegetables include promoting bone health, a functioning immune system, and proper digestion.

Most people in the U.S. do not eat enough fruits and vegetables, while those living at or below the poverty line consume even less. However, food assistance programs, such as SNAP and WIC, and shopping for affordable produce, can help individuals consume more nutritious diets.

View post:
Fruits vs. vegetables: List, nutrition, benefits, and more - Medical News Today

Health and Nutrition 101: Advocating for Your Health Can Save Your Life – San Clemente Times

Posted: at 1:45 am


SUPPORT THIS INDEPENDENT JOURNALISMThe article youre about to read is from our reporters doing their important work investigating, researching, and writing their stories. We want to provide informative and inspirational stories that connect you to the people, issues and opportunities within our community. Journalism requires lots of resources. Today, our business model has been interrupted by the pandemic; the vast majority of our advertisers businesses have been impacted. Thats why the SC Times is now turning to you for financial support. Learn more about our new Insiders program here. Thank you.

JOIN NOW

By Gina Cousineau

As a nutritionist, most people come to me for weight loss, but due to my training in integrative and functional nutrition, my goal is to help my clients live long, healthy, independent, joyful lives.

So, along with a sustainable nutrition approach to lose the weight and keep it off, it is imperative that I teach them to take responsibility for advocating for their health and, in turn, their lives.

All too often clients share with me that their physicians didnt recommend preventative screenings, nor communicate that out of range lab values were concerning. With this, I have uncovered a host of health concerns that threaten to lead to years of disability and shorten my clients lives.

Here is a list of labs, covered by insurance, which I believe are warranted, and necessary, for all ages, along with a host of preventative screenings suggested along the lifespan:

Preventative Screening Tests:

This year alone in my patient population, we have uncovered colorectal cancer in a client nine years overdue for a colonoscopy, an epidemic of osteoporosis and osteopenia (thinning bones), and significant cardiovascular disease, all of which were preventable, treatable, and/or curable, with regular screening and testing.

When looking at these tests above, I too often hear of patients whose blood lipids were out of range, or pre-diabetic, and told simply to lose weight, eat healthier, and exercise.

While our medical care system doesnt allow for the time necessary to further assess risk, I help my clients look at these areas in-depth, assessing family and personal medical histories, accounting for past nutrition and exercise experiences, along with these tests/screenings.

In most cases, I insist on a deeper dive to assess risk, with additional labs and screenings, usually with the appropriate medical specialists, like a cardiologist and endocrinologist.

My recommendation is to start with a primary care provider that is a good listener. Go to healthcare.gov, as well as your insurance provider, and print out these lists of recommended labs and screenings to discuss at your next appointment and be ready to advocate for your health and life.

Gina Cousineau sees clients virtually and in person out of her San Clemente office. Her extensive educationa BS in dietetics and MS in integrative and functional nutritionchef training, and 30-plus years as a fitness professional allow her to help clients lose weight and improve their health. You can reach her at mamag@mamagslifestyle.com, 949.842.9975, and on Instagram and Facebook @mamagslifestyle. Register for her complimentary weekly newsletter at mamagslifestyle.com.

Related

BECOME AN INSIDER TODAYTrustworthy, accurate and reliable local news stories are more important now than ever. Support our newsroom by making a contribution and becoming a subscribing member today.

CONTRIBUTE NOW

View post:
Health and Nutrition 101: Advocating for Your Health Can Save Your Life - San Clemente Times

Infant Nutrition Market Size to Reach Revenues of USD 106.84 Billion by 2026 – Arizton – PRNewswire

Posted: at 1:45 am


CHICAGO, Aug. 11, 2021 /PRNewswire/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global infant nutrition market report.

The infant nutrition market is expected to grow at a CAGR of over 7.70% during the period 20202026.

Key Highlights Offered in the Report:

Key Offerings:

Get your sample today! https://www.arizton.com/market-reports/infant-nutrition-market-size-analysis

Infant Nutrition Market Segmentation

Infant Nutrition Market by Product Type

Infant Nutrition Market by Forms

Infant Nutrition Market by Distribution Channels

Infant Nutrition Market Dynamics

Presently, health-conscious consumers have become increasingly curious about how the foods they consume are manufactured, especially those for children. The concept of organic products precedes the environmental aspects, including traceability, quality, and the feeling of naturalness. Organic products are grown or processed without synthetic fertilizers or pesticides. Most markets are shifting toward natural claims that are not category-specific and in the pediatric nutrition area. Therefore, sustainability and health care concerns are propelling the demand for organic infant nutrition products. Furthermore, the keen interest among parents to procure organic infant nutrition products and ensure sustainability is driving the demand for organic infant formulas. In 2019, nearly 10% of the global new product launches for infant formulas featured an organic claim, increasing by 7% since 2015.

Key Drivers and Trends fueling Market Growth:

Infant Nutrition Market Geography

In 2020, APAC accounted for the largest revenue share of 44.69%. The growth of the region is majorly driven by increasing awareness among consumers regarding infant nutrition and huge growth opportunities for infant formula in the lower-tier cities in countries such as China. Also, the region is witnessing a substantial increase in consumer base and consumers purchasing power. Hectic lifestyle and growing awareness of the health benefits of organic food have encouraged consumers to opt for more organic and natural infant nutrition products. Moreover, rising disposable income has increased the purchasing power of consumers, which is encouraging them to opt for personalized infant nutrition to meet the needs of their babies.

Get your sample today! https://www.arizton.com/market-reports/infant-nutrition-market-size-analysis

Infant Nutrition Market by Geography

Major Vendors

Other Prominent Vendors

Explore our health & wellnessprofile to know more about the industry.

Read some of the top-selling reports:

About Arizton:

AriztonAdvisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Mail: [emailprotected]

Call: +1-312-235-2040+1 302 469 0707

SOURCE Arizton Advisory & Intelligence

More here:
Infant Nutrition Market Size to Reach Revenues of USD 106.84 Billion by 2026 - Arizton - PRNewswire

How PHD Weight Loss and Nutrition takes a unique, individualized approach to wellness | GVLtoday – AVLtoday

Posted: at 1:45 am


The team at PHD Weight Loss and Nutrition in Greenville is made up of health coaches, nutritionists, life coaches + certified PHD consultants, along with an advisory board of physicians and PhDs in psychology. The PHD team works collaboratively under the guidance of PHD owner & founder, Dr. Ashley Lucas, PhD Nutritionist and Registered Dietitian. | Photo provided

Owned and operated by Dr. Ashley Lucas, PhD, RD, PHD Weight Loss and Nutrition offers healthy and sustainable weight loss. They make the overwhelming and daunting task of dropping weight feasible and supportive, understanding that weight gain isnt your fault and that the body is much more complicated than calories in + out.

Thats why PHD takes a truly different approach than most weight loss and nutrition programs. They look at each client as a whole person, evaluating the mental and emotional habits and behaviors that play into why we eat the way we eat.

From there, PHDs team of experts guides clients to enter into their optimal weight in which they will experience a faster, more efficient metabolism and ultimately have the best chance of success in maintaining their weight loss. And with the programs free-for-life maintenance program, 85% of clients who participate maintain their weight loss within 3 lbs.

PHD identifies each clients optimal weight number based on accurate body composition analysis (which varies dramatically for each individual) not based on a generic, random goal weight.

The reason why most people experience the frustrating yoyo phenomenon is because they only let go of a portion of their excess fat weight. That excess fat weight that we carry is active secreting hormones that make us hungry, make us crave, slow our metabolism + make us not want to move. Thats why PHD encourages clients to participate in their program when they are 100% committed to fully collapsing the fat mass.

But when clients are bought in, it works. PHD is based on science, 15+ years of education and training in nutrition and weight management, and clinical experience working with thousands of clients.

Learn more and download Dr. Lucass new book, The Ultimate Weight Loss Secrets, for free online, or call 864-252-4925 for a consultation.

Original post:
How PHD Weight Loss and Nutrition takes a unique, individualized approach to wellness | GVLtoday - AVLtoday

Global Medical Feed Additives Market Report 2021 Featuring Zoetis, Cargill, CHS, Purina Animal Nutrition and ADM Co – Long-term Forecast to 2025 &…

Posted: at 1:45 am


DUBLIN, Aug. 13, 2021 /PRNewswire/ -- The "Medical Feed Additives Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global medical feed additives market is expected to grow from $11.2 billion in 2020 to $13.3 billion in 2021 at a compound annual growth rate (CAGR) of 18.8%. The market is expected to reach $16.65 billion in 2025 at a CAGR of 5.8%.

Major players in the medical feed additives market are Zoetis Inc., Cargill, CHS Inc., Purina Animal Nutrition (Land O' Lakes) and Archer Daniels Midland Company.

The medical feed additives market consists of sales of medical feed additives and related services in order to prepare complete food for animals. Medical feed additives help improve the nutritional content and quality of feed, results in better productivity, and prevents animals from diseases. Medical feed additives industry includes companies that produce animal feed additives such as vitamins and probiotic, preservatives, antioxidants, digestibility enhancers, gut flora stabilizers and others.

The overuse and inappropriate use of antibiotics in medical feed additives impacts the health of individuals consuming the animal meat or other related products. Moreover, the health of the animal consuming the feed may also be adversely affected by the antibiotics added to the feed as the excess additive reduces the natural immunity of the animal and increases susceptibility of the livestock to infections.

For instance, on July 1 2020, the Ministry of Agriculture and Rural Affairs in China, under Announcement No. 194 banned the production of commercial feed with medicated feed additives (excluding traditional Chinese medicine) for growth promoting purposes The negative effects of additives on human health caused due to overuse of feed additives in animals will restrain the growth of the market.

Increase in prevalence of diseases among animals is driving the growth of the medicated feed additives market According to the estimates from report by Animal and Plant Health Agency, a total of 3289 number of new TB herd incidents were detected in England. A new herd incident is a case of bovine TB that occurs as a result of a herd or individual animal test performed in an officially TB-free (OTF) herd during the study period.

Story continues

Bovine tuberculosis is a chronic disease which usually affects animals such as cattle, but it can affect all mammals causing illness, coughing and eventual death. Moreover, according to the reports the herd incidence rate in England for the 12 months to end September 2020 was 9.4.The additives help prevent animals from diseases alongside increasing the nutrition level of the feed thereby increasing demand for feed additives.

In February 2019, Archer Daniels Midland Company (ADM), an American global food processing and commodities trading company acquired Neovia for $1.74 billion (1.544 billion). This acquisition helps ADM to become a global leader in animal nutrition products and services with Neovia adding a wide range of products to the former company's portfolio including pet care, additives, aquaculture, and livestock feed which would in turn boost the growth of the company. Neovia is headquartered in France was established in 1954 and manufactures and distributes various biologically degradable disinfectants along with feed additives for plants and animals.

Companies in the medical feed additives market are introducing new feed medicated additives formed as a result of combination of two or more medicated feed additives. More than 70% of manufacturers are now using more than one feed additive in animal feed to increase the efficiency of the product.

For instance, Zoetis, a global health company got the approval for its Cyden and Lincomix combination feed additive from the FDA (Food and Drug Administration) and is proposed to be used as medicated feed additive for poultry. Also, FDA approved combination of Zoetis' feed additives ACTOGAIN 45 (ractopamine hydrochloride) and ENGAIN (ractopamine hydrochloride) that makes more lean muscle and less fat while optimizing feed efficiency.

The medical feed additives market is regulated by government agencies which lay down regulations to be followed by all the manufacturers of veterinary medicines.

Key Topics Covered:

1. Executive Summary

2. Medical Feed Additives Market Characteristics

3. Medical Feed Additives Market Trends And Strategies

4. Impact Of COVID-19 on Medical Feed Additives

5. Medical Feed Additives Market Size And Growth 5.1. Global Medical Feed Additives Historic Market, 2015-2020, $ Billion 5.1.1. Drivers of the Market 5.1.2. Restraints on The Market 5.2. Global Medical Feed Additives Forecast Market, 2020-2025F, 2030F, $ Billion 5.2.1. Drivers of the Market 5.2.2. Restraints on the Market

6. Medical Feed Additives Market Segmentation 6.1. Global Medical Feed Additives Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Antioxidants

Antibiotics

Probiotics & prebiotics

Enzymes

Amino acids

6.2. Global Medical Feed Additives Market, Segmentation By Livestock, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Ruminants

Poultry

Swine

Aquaculture

6.3. Global Medical Feed Additives Market, Segmentation By Mixture Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Supplements

Concentrates

Premix Feeds

Base Mixes

6.4. Global Medical Feed Additives Market, Segmentation By Class type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7. Medical Feed Additives Market Regional And Country Analysis 7.1. Global Medical Feed Additives Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion 7.2. Global Medical Feed Additives Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/qjzpnq

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

Cision

View original content:https://www.prnewswire.com/news-releases/global-medical-feed-additives-market-report-2021-featuring-zoetis-cargill-chs-purina-animal-nutrition-and-adm-co---long-term-forecast-to-2025--2030-301355059.html

SOURCE Research and Markets

Read the original here:
Global Medical Feed Additives Market Report 2021 Featuring Zoetis, Cargill, CHS, Purina Animal Nutrition and ADM Co - Long-term Forecast to 2025 &...

The #1 Worst Bagel to Order at Panera Bread, Dietitian Says – Eat This Not That – Eat This, Not That

Posted: at 1:45 am


Ooh, that feeling of anticipation when you're browsing Panera's bagel baskets to decide which pick you're in the mood for. But, if you're like a lot of bagel lovers, you know "bagel" is synonymous with "serious carbs." We're here to help: After Panera Bread's announcement last week that their company is about to go bigger, we teamed with a dietitian to research the Panera bagels (and cream cheese choices!) that are safe bets, if you're being mindful of your weight and health as well as the one Panera bagel you should probably save for super-special occasions.

Dina R. D'Alessandro, MS, RDN, CDN is a registered dietitian nutritionist and lecturer at the City University of New York's Herbert H. Lehman College. D'Alessandro has reviewed Panera Bread's nutritional information to hone in on the best and worst bagels and cream cheese at America's biggest bakery chain. Keep readingand, while we're talking morning must-haves, check out D'Alessandro's analysis of The #1 Worst Coffee Creamer on Shelves, Says Dietitian.

per 1 bagel: 420 calories, 7 g fat (5 g saturated fat), 380 mg sodium, 83 g carbs (2 g fiber, 32 g sugar), 9 g protein

Let's slice right in: D'Alessandro says the worst bagel at Panera Bread is their Cinnamon Crunch Bagel. ("Sadly, my personal favoritehaha!" she reveals.)

We know you might share this fave, but D'Alessandro notes that the Cinnamon Crunch Bagel comes in at the most calories per serving, with 420. This is "a little high if you're choosing this as a breakfast food," D'Alessandro says, adding that as a dessert option, it may be A-OK.

Sign up for the Eat This, Not That! newsletter for daily food news you can use.

per 1 bagel: 330 calories, 5 g fat (3 g saturated fat), 370 mg sodium, 60 g carbs (2 g fiber, 12 g sugar), 10 g protein

"Again, fine if this is a dessert option," D'Alessandro says about Panera's Chocolate Chip Bagel, "but I'd be mindful of the 60 grams of carbs and 12 grams of sugar in one serving." ("Compare this to approximately 30 grams of carbs and three grams of sugar in two slices of plain bread," she suggests.)

RELATED:The Best & Worst Chocolate in AmericaRanked!

per 1 bagel flat: 180 calories, 2 g fat (0 g saturated fat), 410 mg sodium, 34 g carbs (3 g fiber, 4 g sugar), 7 g protein

Perhaps not a surprise, D'Alessandro says Panera's Sprouted Grain Bagel Flat contains the lowest calories of all the bagels (180), and only four grams of sugar. "Since this contains some whole grains, it also has slightly more fiber than the other options," she points out.

Why might this matter? A recent study revealed that whole grains impact blood sugar levels, blood pressure, and even your waistline.

per 1 bagel: 280 calories, 1 g fat (0 g saturated fat), 410 mg sodium, 57 g carbs (2 g fiber, 4 g sugar), 10 g protein

You know you're signing up for a treat when you order a bagelso when you want the full-on bagel experience but you don't want to go entirely rogue on nutrition, D'Alessandro says Panera's Plain Bagel is fine. "With four grams of sugar and zero saturated fat," she says, "you can be a little more decadent with your cream cheese spread."

Speaking of Panera cream cheese, she analyzed those, tookeep reading.

per 2 tbsp: 110 calories, 10 g fat (7 g saturated fat), 85 mg sodium, 3 g carbs (0 g fiber, 1 g sugar), 1 g protein

Believe it or not, D'Alessandro says the worst of Panera's cream cheese choices is the Plain. "You would think the simplest option might be the healthiest, but not in this case," D'Alessandro says.

She explains that's "mostly because of its 11 grams of saturated fat . . . about half of the total daily recommended saturated fat intake for a 2,000-calorie diet."

RELATED:The Best and Worst Cream Cheese Spreads, According to RDs

per 2 tbsp: 80 calories, 6 g fat (4 g saturated fat), 115 mg sodium, 1 g carbs (0 g fiber, 1 g sugar), 3 g protein

D'Alessandro points out that Panera's Chive & Onion Cream Cheese contains the lowest calories of all the spreadsbut also, the highest amount of sodium at 190 milligrams. (ReadThe Surprising Effect Reducing Sodium May Have on Your Blood Sugar, New Study Says.)

per 2 tbsp: 80 calories, 6 g fat (3.5 g saturated fat), 105 mg sodium, 5 g carbs (0 g fiber, 5 g sugar), 2 g protein

D'Alessandro calls Panera's Honey Walnut Cream Cheese "a good, overall distribution of calories, fat, and protein." She adds that if you stick with the two-tablespoon portion size, this delivers a cream cheese fix that's "not too sweet (with eight grams of sugar) in comparison to other spreads, but sweet enough to enjoy the natural honey flavor."

Are you curious how the Honey Walnut Cream Cheese has better nutrition facts than Plain? D'Alessandro shares something you might find unexpected: "Technically, the Honey Walnut Cream Cheese is reduced-fat, which is why it has less calories than its plain, full-fat counterpart." She explains that this isn't mentioned on the individual product name"but it is mentioned on the Nutrition Info PDF and in the ingredients list."

So, the Cinnamon Crunch is maybe not your bestie after all but if a Sprouted Grain Bagel Flat with Honey Walnut Cream Cheese sounds appetizing, this could be a nutrition-friendly swap instead.

Keep reading:

Go here to read the rest:
The #1 Worst Bagel to Order at Panera Bread, Dietitian Says - Eat This Not That - Eat This, Not That

Latest Nutrients Review Paper Explores Potential Benefits of Bovine Colostrum in Pediatric Nutrition and Health – Business Wire

Posted: at 1:45 am


PHOENIX--(BUSINESS WIRE)--PanTheryx, an integrative digestive and immune health company, today announced the publication of the latest scientific paper titled, Potential Benefits of Bovine Colostrum in Pediatric Nutrition and Health in the peer-reviewed journal Nutrients. The use of cow colostrum has been clinically demonstrated in human health, and the current comprehensive review puts a spotlight on the potential health benefits of cow colostrum in a pediatric population.

Im pleased to see more scientific focus on the use of cow colostrum for different ages and stages of life. We already know the tremendous health benefits of human colostrum for creating a foundation for an infants digestive and immune systems, said Lauren Crosby, MD, FAAP, pediatrician and scientific advisor for PanTheryx. The latest publication in Nutrients provides a glimpse of scientific opportunities for cow colostrum in regard to gut and respiratory infections in children, multiple gastrointestinal disorders in children as well as the potential for supporting gut health in infants.

The Next Frontier Cow Colostrum and Pediatric Nutrition

The current pediatric scientific paper is a part of the Nutrients Special Issue series on colostrum and gives the research community a comprehensive review of cow colostrum for a pediatric population, including exploration of the nutritional and bioactive components of cow colostrum, product consistency, recommended safe and effective intake levels, and processing procedures.

Cow colostrum features milk proteins, immunoglobulins, oligosaccharides, lactoferrin, growth factors, dairy lipids as well as several other components that support immune modulation, have anti-microbial properties, and promote cell growth in children and adults. The body of science showing health benefits for early life nutrition continues to grow with the latest research showing how cow colostrum can support a childs natural immune response to common respiratory illnesses (URTIs) and its effectiveness in helping to relieve diarrhea in children.

The Nutrients special series on cow colostrum is an insightful resource for nutrition researchers, product manufacturers and health-conscious consumers who want to better understand how colostrum can impact their digestive and immune health across the lifespan, commented Mike Weiser, PhD, director of innovation at PanTheryx. We are hopeful more research focused on the health benefits of cow colostrum will be conducted, and look forward to making high-quality nutritional ingredients easily accessible to consumers.

Nutrients is an open access peer-reviewed scientific journal that publishes reviews, regular research papers and short communications on all aspects of nutrition. This Nutrients series on bovine colostrum is underwritten by PanTheryx.

To stay updated on the comprehensive health benefits of cow colostrum, please visit http://www.colostrum101.com. To learn more about PanTheryx, please visit http://www.pantheryx.com.

About PanTheryx

PanTheryx is a nutrition and biotechnology company committed to the broad commercialization of health and wellness solutions for the global human and animal health markets. As the worlds largest producer of bovine colostrum, PanTheryx utilizes the cellular and biomolecular processes of bovine colostrum to develop and produce a wide range of nutritional health and wellness products. PanTheryxs proprietary colostrum, ColostrumOne is natures superfood; designed to be comprehensive as nature intended with the important nutritional components for health and vitality throughout all stages of life. Founded in 2007, PanTheryx is headquartered in Phoenix, Arizona. Production facilities are located in Phoenix, AZ and Ripon, CA. To learn more, please visit http://www.pantheryx.com.

Read more here:
Latest Nutrients Review Paper Explores Potential Benefits of Bovine Colostrum in Pediatric Nutrition and Health - Business Wire

Barnyard Basics: Make sure cows have adequate nutrition on a dry year – Post Register

Posted: at 1:45 am


Cows need different nutritional levels at different stages of gestation. As the fetus grows larger, the cows nutrient needs increase. If a cow is lactating, feeding her calf, she needs a much higher level of protein and energy than when she is pregnant.

Janna Block (Livestock Systems Specialist, Hettinger Research Extension Center, North Dakota State University) says this year with drought conditions may be more challenging to get cows through winter and feed them adequately.

People in our area have been putting up every scrap of forage they can find, to make hay, and some will be using alternatives the cattle are not used to eating. Some people have asked about harvesting cattails for hay; sloughs have dried up and the cattails might make a bale. Weve also had questions about flax and canola and small grains being put up for hay instead of harvested. A lot of poor-doing wheat crops are being put up for hay, she said.

Depending on the stage of maturity when a cereal crop is cut, it might make good hay but if its too mature it will be a bit of grain and straw mainly straw if the grain didnt fill out.

About 65% of the alfalfa in the U.S. is suffering from drought. Alfalfa may not be available in some areas and a lot of what is put up was already tapped for export markets or going to dairies. Beef producers will have to find something else, she said.

Some regions have had a little rain and people in those areas may be able to get through the grazing season and keep cows on pasture but may not have an extended grazing season this year.

Some stockmen are regretting that they left cows out grazing so late last fall because there wasnt any residue forage this spring and no forage base going into this years drought. It was a mild winter so they didnt bring cattle in to feed hay, and then the grass didnt grow very well this spring, Block said.

Some people fed up everything they had because it was a slow, cold spring and pastures were slow growing. Hay production this year has been short.

Even with some late-season rains, hay supply in some regions is only about 25% to 50% of normal. Some hay fields didnt grow enough to cut. Hay prices are high; were looking at $175 a ton for grass hay, and $250 and higher for alfalfa. People with large herds will have a hard time making that pencil out, and well see a lot of cows sent to market.

On a dry year, feed testing and nutrient analysis becomes very important. There are many factors that influence quality.

When looking at native grass pastures there is no formula for how the nutrient quality might be affected. It depends on when the drought occurred during the growing season, how long it lasts and how severe it is. All these things can affect quality, said Block. My best advice to ranchers is to make sure you know exactly what youve got, in terms of nutrient quality, and carefully monitor body condition of the cows. Many people are considering early weaning.

Weaning is a good time to evaluate body condition of the cow. Once the calf is weaned (removing the requirements for lactation) this is the best time to improve the body condition of cows, with least cost. If you wait until late gestation and their requirements are increasing, it will be harder.

If cows are out at pasture, we tell people to check their manure. If its firm and dry, those cows are not getting enough protein. They could utilize the dry forage better if they had a protein supplement, and might not lose as much weight, she said.

Some of the small grains like sorghum sudan and canola, and other alternative forages might help fill the gap, but many of these are nitrate accumulators, especially in a drought. Its imperative to check these for nitrate levels as well as nutrients before you feed them to pregnant cows.

We dont want cows to abort, and this can be a common consequence of nitrate toxicity; it shuts off the oxygen supply to the developing fetus. Those cows will abort at various times during gestation if they are consuming too much nitrate in the forage, said Block.

Oat hay or straw (and sometimes barley) may also have high nitrates under certain growing conditions.

Take a look at your forage and feed resources and make a plan for how to use them best, especially for the heifers and young cows. They are still growing and its harder to meet their needs for growth and lactation.

They also dont have as much rumen capacity as mature cows, and need a higher plane of nutrition, with higher-quality feed. This is why it is important to do feed tests and get a nutrient analysis and be able to make a plan for the different age groups, said Block.

Do an inventory on the feed youd need for replacement heifers and for the young cows, the bulls and the main cow herd.

We should group cattle by age and stage of production, figuring out how to use our feed most effectively. It can be challenging if you only have a certain number of pens or pastures. This year may require more adjustments and innovation, Block said.

You might be able to split pastures with temporary electric fencing, to be able to feed certain groups a higher quality forage or feed them separately.

If you have thin cows, weaning early is probably one of the best options to consider, to make sure cows have time to recover before colder weather (when feed requirements increase) and late gestation (when requirements for pregnancy are greatest), Block said.

Go here to see the original:
Barnyard Basics: Make sure cows have adequate nutrition on a dry year - Post Register

Roundup: Thriva launches mobile app, digital revolution in social care to bring 127M boost and more briefs – Mobihealth News

Posted: at 1:45 am


PILATUS OFFERS MEDEVAC WITH EPISHUTTLE

Together with its development partner, Aerolite AG, Swiss aerospace manufacturer, Pilatus now offers integration of the EpiShuttle in medevac PC-24s.

Created out of the growing demand for air transport solutions for infectious patients during the COVID-19 pandemic, the solution prevents in-flight transmission of viruses to cockpit and cabin crew.

Patient monitoring is ensured by medical equipment placed on a cradle right next to the EpiShuttle and powered by the on-board power supply. As with regular patient transport operations, medical personnel occupy cabin seats in the vicinity of the EpiShuttle, and can attend to the patient.

Ellen Cathrine Andersen, CEO in EpiGuard, said: "We are glad to see that Pilatus offers the very best patient comfort and safety. With the EpiShuttles features of reclinable backrest, transparent hard-top and excellent patient access, their passengers, both patient and staff, will have a safer and better ride. We are also impressed by Aerolites ingenuity when integrating the EpiShuttle into the medevac PC-24, an excellent aircraft for the transfer of infected patients with the EpiShuttle."

THRIVA LAUNCHES MOBILE APP TO TRACK HEALTH

UK-based self-monitoring health app, Thriva has launched its first mobile app that enables people to track their health on the go.

The new app offers access to Thriva services in a secure and private app. Users can access personalised home blood tests, and GP health advice. The app will enable customers to receive instant updates and track their progress on their phone.

Hamish Grierson, CEO & co-founder of Thriva, said: We expect to manage every element of our lives at the touch of a button - from our money, to how we travel and now, our health. Thrivas new app puts better health at your finger-tips with the support you need to understand and improve your health, on the go. This is another step forward on our journey to increase the Health Span of millions of people.

AI IN BARTS HEALTH SPARES LIMB AMPUTATION

Barts Health NHS trust has deployed new AI technology, supplied by Clinithink, to scan 14.2 million documents to find patients with diabetic foot disease, a potentially serious complication of diabetes.

The software scannedthrough medical records and notes to find 30% more patients with diabetes and 375% more patients with diabetic foot problems, making it easier for clinicians to schedule earlier treatments to save feet and limbs from amputation.

Attempting this scale of analysis manually would have been frankly impossible, said Dr Charles Gutteridge, chief clinical information officer at Barts Health. Theoretically it would have taken one clinician over a hundred years to review that volume of documents. So not only does AI technology help us find patients who we couldnt otherwise find, it also saves precious clinical time. This is a first and most important step in being able to treat many patients earlier than would have been possible using a manual process to find them and preventing the serious complications that may result in amputation.

In the next phase of work planned by the Barts Health team, the characteristics extracted by the software in the cohort it identified, will be used to determine whether this approach can predict which patients are most likely to develop the complications associated with Diabetic Foot Disease (DFD).

SAMSUNG AND LIFESUM PARTNER FOR WATCH4 SERIES

Swedish-based global nutrition app, Lifesum has announced that it is a leading nutrition partner on the new Samsung Galaxy Watch4 series, enabling users to track nutrition and increase daily health.

Unveiled at Samsung Unpacked event on 11 August, Galaxy Watch4 and Galaxy Watch4 Classic are Samsung's next smartwatches with holistic wellness tracking.

The smartwatches will run Wear OS Powered by Samsung and are built jointly with Google. Features include a food tracker, which will help users log meals and track calorie intake, and a water tracker to make staying hydrated during the day more convenient. The Galaxy Watch4 and Galaxy Watch4 Classic will sync with Lifesum on smartphones, so users can monitor their exercise and reach personal fitness goals.

The Galaxy Watch4 services will be available beginning 27 August.

HEALTHCARE FIRMS HELP EUROPEAN UNICORNS SET RECORD PACE

According to investment monitoring platform Pitchbook, 23 European and Israeli unicorn companies, valued at a billion or more, have already completed a record amount of deals this year.

Closing in on 2020's total of 38, the approximate market value of unicorns in Europe also grew to 122.5 billion in Q1 2021. Furthermore, healthcare technology investment grew by 47% in 2020 to a new sector high of $51 billion.

World Nano Foundation co-founder, Paul Sheedy welcomed the increased financial backing for healthcare innovation: "COVID-19 pushed the over-centralised global healthcare systems to their limit in 2020, so it's very promising to see investors supporting and driving the healthtech sector forward that supports early intervention and prevention delivered at the point of care, but this must continue, as the next decade will be pivotal in shaping the future of healthcare."

DIGITAL REVOLUTION IN SOCIAL CARE TO BRING 127M

An analysis of NHS Digitals Social Care Programme found that a drive to expand the use of digital technology in social care is expected to lead to 127 million worth of benefits.

The report also found that new ways of working with digital technology will reduce hospital admissions and GP visits, as well as improve quality of life.

The programme aimsto harness the power of information and technology to help Englands social care sector care for people more and effectively and efficiently.

James Palmer, programme head of the social care programme at NHS Digital, said:We are delighted to see the impact that digital technology introduced through our programme has already had on peoples lives and the multitude of benefits it will bring in the years to come, both on individuals and on the wider health and social care sector.

Our approach throughout has been led by users of the services and we have worked collaboratively with care providers and local authorities, which has given us high confidence they can deliver outcomes and benefits for those commissioning, providing and receiving care.

VODAFONE AND MY MHEALTH

UK-based digital therapeutics company, my mhealth has announced the first international rollout of its NHS-approved COPD app, myCOPD in New Zealand.

The rollout is initially focused on the Mori and Pasifika population, making it the first NHS approved digital self-management programme for COPD to be available in a clinical setting beyond British borders.

Within one District Health Board (DHB), around 300 patients will be the first in the country to have access to the app, with an aim to expand patient access.

myCOPD provides patients with access to a digital self-management programme, assisting with inhaler technique with inhaler videos, access to online pulmonary rehabilitation and learning how to manage their COPD from experts. Through this platform, healthcare professionals are also able to remotely monitor symptoms of COPD.

See the original post:
Roundup: Thriva launches mobile app, digital revolution in social care to bring 127M boost and more briefs - Mobihealth News

Aluminum and Alzheimer’s disease: after a century of …

Posted: August 2, 2021 at 1:54 am


The brain is a highly compartmentalized organ exceptionally susceptible to accumulation of metabolic errors. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of the elderly and is characterized by regional specificity of neural aberrations associated with higher cognitive functions. Aluminum (Al) is the most abundant neurotoxic metal on earth, widely bioavailable to humans and repeatedly shown to accumulate in AD-susceptible neuronal foci. In spite of this, the role of Al in AD has been heavily disputed based on the following claims: 1) bioavailable Al cannot enter the brain in sufficient amounts to cause damage, 2) excess Al is efficiently excreted from the body, and 3) Al accumulation in neurons is a consequence rather than a cause of neuronal loss. Research, however, reveals that: 1) very small amounts of Al are needed to produce neurotoxicity and this criterion is satisfied through dietary Al intake, 2) Al sequesters different transport mechanisms to actively traverse brain barriers, 3) incremental acquisition of small amounts of Al over a lifetime favors its selective accumulation in brain tissues, and 4) since 1911, experimental evidence has repeatedly demonstrated that chronic Al intoxication reproduces neuropathological hallmarks of AD. Misconceptions about Al bioavailability may have misled scientists regarding the significance of Al in the pathogenesis of AD. The hypothesis that Al significantly contributes to AD is built upon very solid experimental evidence and should not be dismissed. Immediate steps should be taken to lessen human exposure to Al, which may be the single most aggravating and avoidable factor related to AD.

See more here:
Aluminum and Alzheimer's disease: after a century of ...

New research links COVID-19 and signs of Alzheimer’s disease – Medical News Today

Posted: at 1:54 am


Scientists presenting research at the AAIC 2021, held online and in Denver, CO, have found links between COVID-19 and longer-term cognitive issues, including biological signs of Alzheimers disease.

The findings lay the ground for larger longitudinal studies to explore in more detail the neurological effects of COVID-19.

COVID-19 is primarily a respiratory condition. The Centers for Disease Control and Prevention (CDC) note that COVID-19 symptoms can include mild respiratory problems, more severe low oxygen levels and shortness of breath, and life threatening issues affecting multiple organs across a persons body.

Much research has been done to understand these acute symptoms, and there are now many different treatment options open to clinicians.

However, the effects of COVID-19 do not always end after the acute phase of the condition.

As the pandemic progressed, anecdotal evidence suggested many people who had recovered from COVID-19 were still experiencing a variety of symptoms. This became known as long COVID.

According to Dr. A. V. Raveendran, of the Government Medical College in Manjeri, India, and his colleagues, symptoms of long COVID can include profound fatigue, breathlessness, cough, chest pain, palpitations, headache, joint pain, myalgia and weakness, insomnia, pins and needles, diarrhea, rash or hair loss, impaired balance and gait, neurocognitive issues, including memory and concentration problems, and worsened quality of life.

At the AAIC 2021, researchers presented a number of studies that focus on the neurological issues associated with the longer-term effects of COVID-19.

According to Dr. Heather M. Snyder, Alzheimers Association vice president of medical and scientific relations, [t]hese new data point to disturbing trends showing COVID-19 infections leading to lasting cognitive impairment and even Alzheimers symptoms.

With more than 190 million cases and nearly 4 million deaths worldwide, COVID-19 has devastated the entire world. It is imperative that we continue to study what this virus is doing to our bodies and brains. The Alzheimers Association and its partners are leading, but more research is needed, she said.

In one study, Dr. Gabriel De Erausquin, of the University of Texas Health Science Center at San Antonio Long School of Medicine, as well as colleagues from the Alzheimers Association leading a consortium on links between COVID-19 and the nervous system, looked at neurological issues in Amerindians from Argentina who had recovered from acute COVID-19.

The 300 participants were assessed 36 months after having COVID-19. The researchers found that more than 50% of the participants had issues with forgetfulness and that around 25% also experienced executive dysfunction and language issues.

The researchers noted an association between these cognitive issues and loss of smell but not with the severity of the initial SARS-CoV-2 infection.

According to Dr. Erausquin, [we are] starting to see clear connections between COVID-19 and problems with cognition months after infection.

[It is] imperative we continue to study this population, and others around the world, for a longer period of time to further understand the long-term neurological impacts of COVID-19.

In another study presented at the conference, Prof. Thomas M. Wisniewski, professor of neurology, pathology, and psychiatry at New York University Grossman School of Medicine, and his colleagues explored the possible links between COVID-19 and clinical signs of Alzheimers disease.

The researchers took blood plasma samples from 310 people who had been admitted to hospital with COVID-19. Of those, 158 had neurological symptoms associated with COVID-19 most frequently, confusion while 152 did not.

In the patients who did not have cognitive issues prior to developing COVID-19 but then did develop neurological symptoms, the researchers found an increase in biological markers associated with Alzheimers disease, brain injury, and neuroinflammation, compared with the patients who did not have neurological symptoms.

These included total tau, neurofilament light, glial fibrillary acid protein, phosphorylated tau, and ubiquitin carboxyl-terminal hydrolase L1. The researchers also noted a correlation between some of these markers and C-reactive peptide.

Prof. Wisniewski explains: These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimers-related symptoms and pathology. However, more longitudinal research is needed to study how these biomarkers impact cognition in individuals who had COVID-19 in the long term.

Researchers also presented findings looking at the relationship between cognitive issues linked to COVID-19, and peoples physical condition and blood oxygen levels.

Dr. George D. Vavougios, a postdoctoral researcher for the University of Thessaly in Greece, and his colleagues recruited 32 people who had been hospitalized with mild or moderate COVID-19 and then discharged 2 months later.

Just over half of the participants had issues with cognitive decline, including short-term memory impairment as well as multidomain impairment without short-term memory issues.

The researchers found a correlation between worse levels of cognitive scores and being older, having a larger waist circumference, and a higher waist-to-hip ratio.

The participants also took a 6-minute walking test. After accounting for sex and age, the researchers found a link between worse memory and thinking scores and lower blood oxygen levels.

Dr. Vavougios says: A brain deprived of oxygen is not healthy, and persistent deprivation may very well contribute to cognitive difficulties. These data suggest some common biological mechanisms between COVID-19s dyscognitive spectrum and post-COVID-19 fatigue that have been anecdotally reported over the last several months.

The research presented at the conference is also supported by a new study published in The Lancet, which drew on data from over 80,000 participants. Having accounted for a range of factors, the researchers behind this study found that people who had recovered from COVID-19 had significant cognitive issues, compared with a control group.

Speaking to Medical News Today, Dr. Adam Hampshire, of the Department of Brain Sciences, Dementia Research Institute, Care Research and Technology Centre, Imperial College London in the United Kingdom, and the corresponding author of the study, said the study emerged out of ongoing research he was conducting when the pandemic took hold.

By coincidence, when the pandemic accelerated in the U.K., I was in the process of collecting one of the largest online surveys of cognitive abilities to have been conducted.

He went on to say: Several peers wrote to me noting that the study could be extended to address questions about the potential impact of the virus, and of the pandemic more broadly, on cognition and mental health. I had been thinking along similar lines so decided to try and help address this important question.

Dr. Hampshire said that the findings make clear a link between cognitive dysfunction and COVID-19 but that more research needs to be done to confirm these findings, explore them in more detail, and understand what, if any, causal mechanisms may be underlying them.

We have identified a worrying association between [COVID-19] illness and cognitive deficits. We also have ruled out many potentially confounding factors.

What is needed is a combination of longitudinal studies that determine how long these deficits last and to disentangle causality, as well as brain imaging studies to understand the underlying neural basis. Such work is underway, and some of those studies are using our assessment software, which I have made available for this purpose.

Dr. Adam Hampshire

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

See the original post here:
New research links COVID-19 and signs of Alzheimer's disease - Medical News Today

Memory Effects Of Long COVID-19 Can Resemble Alzheimer’s : Shots – Health News – NPR

Posted: at 1:54 am


Medical staff members check on a patient in the COVID-19 Intensive Care Unit at United Memorial Medical Center in Houston last November. Doctors are now investigating whether people with lingering cognitive symptoms may be at risk for dementia. Go Nakamura/Bloomberg via Getty Images hide caption

Medical staff members check on a patient in the COVID-19 Intensive Care Unit at United Memorial Medical Center in Houston last November. Doctors are now investigating whether people with lingering cognitive symptoms may be at risk for dementia.

Before she got COVID-19, Cassandra Hernandez, 38, was in great shape both physically and mentally.

"I'm a nurse," she says. "I work with surgeons and my memory was sharp."

Then, in June 2020, COVID-19 struck Hernandez and several others in her unit at a large hospital in San Antonio.

"I went home after working a 12-hour shift and sat down to eat a pint of ice cream with my husband and I couldn't taste it," she says.

The loss of taste and smell can be an early sign that COVID-19 is affecting a brain area that helps us sense odors.

Hernandez would go on to spend two weeks in the hospital and months at home disabled by symptoms including tremors, extreme fatigue and problems with memory and thinking.

"I would literally fall asleep if I was having a conversation or doing anything that involved my brain," she says.

Now, researchers at UT Health San Antonio are studying patients like Hernandez, trying to understand why their cognitive problems persist and whether their brains have been changed in ways that elevate the risk of developing Alzheimer's disease.

The San Antonio researchers are among the teams of scientists from around the world who will present their findings on how COVID-19 affects the brain at the Alzheimer's Association International Conference, which begins Monday in Denver.

What scientists have found so far is concerning.

For example, PET scans taken before and after a person develops COVID-19 suggest that the infection can cause changes that overlap those seen in Alzheimer's. And genetic studies are finding that some of the same genes that increase a person's risk for getting severe COVID-19 also increase the risk of developing Alzheimer's.

Alzheimer's diagnoses also appear to be more common in patients in their 60s and 70s who have had severe COVID-19, says Dr. Gabriel de Erausquin, a professor of neurology at UT Health San Antonio. "It's downright scary," he says.

And de Erausquin and his colleagues have noticed that mental problems seem to be more common in COVID-19 patients who lose their sense of smell, perhaps because the disease has affected a brain area called the olfactory bulb.

"Persistent lack of smell, it's associated with brain changes not just in the olfactory bulb but those places that are connected one way or another to the smell sense," he says.

Those places include areas involved in memory, thinking, planning and mood.

COVID-19's effects on the brain also seem to vary with age, de Erausquin says. People in their 30s seem more likely to develop anxiety and depression.

"In older people, people over 60, the foremost manifestation is forgetfulness," he says. "These folks tend to forget where they placed things, they tend to forget names, they tend to forget phone numbers. They also have trouble with language; they begin forgetting words."

The symptoms are similar to those of early Alzheimer's, and doctors sometimes describe these patients as having an Alzheimer's-like syndrome that can persist for many months.

"Those people look really bad right now," de Erausquin says. "And the expectation is that it may behave as Alzheimer's behaves, in a progressive fashion. But the true answer is we don't know."

Another scientist who will present research at the Alzheimer's conference is Dr. Sudha Seshadri, founding director of the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio.

The possibility that COVID-19 might increase the risk of Alzheimer's is alarming, Seshadri says. "Even if the effect is small, it's something we're going to have to factor in because the population is quite large," she says.

In the U.S. alone, millions of people have developed persistent cognitive or mood problems after getting COVID-19. It may take a decade to know whether these people are more likely than uninfected people to develop Alzheimer's in their 60s and 70s, Seshadri says.

Studies of people who have had COVID-19 may help scientists understand the role infections play in Alzheimer's and other brain diseases. Previous research has suggested that exposure to certain viruses, including herpes, can trigger an immune response in the brain that may set the stage for Alzheimer's.

"If one understands how the immune response to this virus is accelerating [Alzheimer's] disease, we may learn about the impact of other viruses," Seshadri says.

Meanwhile, people like Cassandra Hernandez, the nurse, are simply trying to get better. More than a year after getting sick, she says, her brain is still foggy.

"We were at dinner and I forgot how to use a fork," she says. "It was embarrassing."

Even so, Hernandez says she's improving slowly.

"Before this I was working on my master's," she says. "Now I can do basic math, addition and subtraction, I can read at a fifth-grade level. I'm still working hard every day."

Hernandez has been working with Dr. Monica Verduzco-Gutierrez, chair of the department of physical medicine and rehabilitation at UT Health and director of the COVID-19 recovery clinic.

Verduzco-Gutierrez says her practice used to revolve around people recovering from strokes and traumatic brain injuries. Now she spends some days seeing only patients recovering from COVID-19.

The most common complaint is fatigue, Verduzco-Gutierrez says. But these patients also frequently experience migraine headaches, forgetfulness, dizziness and balance issues, she says.

Some of these patients may never recover fully, Verduzco-Gutierrez says. But she's hopeful for Hernandez.

"She's made so much improvement and I would love for her to go back to nursing," Verduzco-Gutierrez says. "But again, we don't know what happens with this disease."

More here:
Memory Effects Of Long COVID-19 Can Resemble Alzheimer's : Shots - Health News - NPR

New genetically modified mouse model mimics multiple aspects of human Alzheimer’s disease – National Institute on Aging

Posted: at 1:54 am


NIA-supported scientists have developed a new mouse model that produces a form of the human beta-amyloid protein, a hallmark of Alzheimers disease. An important research tool, mouse models enable the exploration of genetic, environmental, and behavioral aspects of Alzheimers, as well as make it possible to test drug candidates before human studies. The new mouse model, which was reported in a recent article in Nature Communications, can be used by other scientists to advance Alzheimers research.

Many factors, including gene changes, the aging process, and conditions in the environment, can promote the gradual development of Alzheimers. NIA invests in research to explore various disease-causing mechanisms and identify drug candidates that might prevent or delay the onset of Alzheimers.

As part of these investments, NIA established the Model Organism Development and Evaluation for Late-Onset Alzheimers Disease (MODEL-AD) consortium to develop new animal models of late-onset Alzheimers, to characterize the models relative to multiple aspects of human disease, and to make all data and models available to researchers in academia and the biotechnology and pharmaceutical industries via the NIA-supported AD Knowledge Portal. To date, the MODEL-AD teams have generated more than 50 new mouse models.

An international team led by researchers at the University of California, Irvine, one of five MODEL-AD consortium institutions, set out to engineer a mouse model that could mimic the molecular pathways that lead to the late-onset, most common form of Alzheimers. This form does not have symptoms before about age 60 and occurs sporadically, rather than in several members of a family.

Most mouse models already being used to study Alzheimers were made to overexpress amyloid precursor protein. But these models are imperfect because the mice overproduce beta-amyloid in addition to other protein fragments.

The University of California, Irvine, research team had a different approach. The team slightly modified a mouse gene so that the mice could develop the human version of beta-amyloid protein. Then the team used the gene knock-in method to insert the modified gene at a specific location. The knock-in method helps scientists study the development of a disease and its effects on the body.

Next, the team analyzed the brains of the genetically modified mice and confirmed the presence of the human beta-amyloid. The protein was produced at normal levels, rather than overproduced, as in most other mouse models.

The team noted that the mice developed behavior changes and cognitive impairment as they grew old, like what occurs in many people with beta-amyloid plaques in their brain. The mice also had changes in gene expression that resembled patterns detected in the brains of people with Alzheimers. When the team blocked the modified gene so that the mice could not develop beta-amyloid, the mice did not develop age-related cognitive impairment.

This new mouse model with human beta-amyloid provides a novel way for researchers to study the aging, genetic, and environmental factors that promote Alzheimers. It can be used to introduce other Alzheimers risk and protective genetics factors and explore how genes and the environment are involved in the disease. In addition, researchers can use this mouse model to test the effectiveness of therapeutic agents.

The project was funded in part by NIA grants R01AG027544, P01AG000538, R21AG054884, U54AG054349, R01AG049562, R01AG056768, and P50AG016573.

These activities relate to NIHs AD+ADRD Research Implementation Milestone 4.A, Support the development of the next generation of animal models based on the current understanding of genetic and environmental risk and protective factors for AD and related dementias, using genome editing and other cutting edge technologies (optogenetics/deep brain stimulation/trans-magnetic stimulation, and next generation in vivo imaging) to facilitate assessment and validation of findings from human studies and Milestone 4.B, Create infrastructure/resources for extensive characterization of existing and new animal models and development of standardized and rigorous methods for preclinical efficacy testing including web-based resources for transparent reporting of both positive and negative findings.

Reference: Baglietto-Vargas D, et al. Generation of a humanized A expressing mouse demonstrating aspects of Alzheimers disease-like pathology. Nature Communications. 2021;12(1):2421. doi: 10.1038/s41467-021-22624-z.

Continue reading here:
New genetically modified mouse model mimics multiple aspects of human Alzheimer's disease - National Institute on Aging

Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate – PMLiVE

Posted: at 1:54 am


Biogen and Ionis have revealed topline data from an early-stage study evaluating its investigational Alzheimers disease drug candidate BIIB080 (IONIS-MAPT Rx).

The phase 1b study of BIIB080 met its primary objective, demonstrating an encouraging safety and tolerability profile in patients with mild Alzheimers disease.

In this study, investigators also noted that BIIB080 demonstrated both robust time- and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period, with sustained reductions also observed in the six-month post-treatment period.

For BIIB080-treated patients, there were dose-dependent decreases in the concentration of total-tau in CSF eight weeks after their last dose. The mean percentage reduction was 30%, 40% and 49% in the low-, medium- and high-dose groups treated every four weeks respectively.

For patients in the group treated every 12 weeks, BIIB080 treatment led to a 42% reduction in the concentration of total-tau in CSF.

After 16 weeks post-dose, total tau in CSF also continued to decline in BIIB080-treated patients in both the high-dose four-week and 12-week groups, with a 55% and 49% reduction from baseline respectively.

"We are encouraged by the topline results from this study of BIIB080, which demonstrate the potential of Ionis' antisense technology to successfully target what we believe is a root cause of Alzheimer's disease," said C Frank Bennett, chief scientific officer and franchise leader for neurological programmes at Ionis.

"These study results support further investigation of BIIB080 for the treatment of Alzheimer's disease and suggest that antisense-mediated suppression of tau protein may be a feasible therapeutic approach for other tauopathies, he added.

"Biogen is encouraged by the results of this trial, and we look forward to our continued research in future clinical studies with this promising investigational asset, said Alfred Sandrock, head of research and development at Biogen.

In June, Biogens aducanumab was approved with the brand name Aduhelm for the treatment of Alzheimers disease, in a landmark moment for the therapy area.

The approval did not go without criticism, however, with The Institute for Clinical and Economic Review (ICER) among others maintaining that the evidence on aducanumab is insufficient to be able to demonstrate that patients get benefits that would outweigh the risks and harms of this treatment.

View original post here:
Biogen and Ionis post 'encouraging' early results for Alzheimer's disease candidate - PMLiVE

Benway will chair the 2021 North Central Ohio Walk to End Alzheimer’s – Richland Source

Posted: at 1:54 am


MANSFIELD Cheryl Benway will lead the communitys efforts to raise money to support Alzheimers care, support and research as the Chair of the 2021 North Central Ohio Walk to End Alzheimers.

The North Central Ohio Walk is Saturday, Sept. 11, and participants this year will be able to physically join forces to recreate the driving movement and energy that fuels the fight to end Alzheimers.

The Walk will take place in-person at OSU/NCSC Campus in Mansfield. The Promise Garden and Display Area open at 9 a.m. and the Walk Ceremony begins at 10 a.m. Participants will walk on a paved path around campus at the close of the ceremony.

Julia Pechlivanos, Executive Director of the Alzheimers Association Northwest Ohio Chapter, said the Chapter is excited to move back to an in-person Walk experience this year because it offers the opportunity for people who have been impacted by dementia including caregivers, family, friends, and colleagues, to share their stories with one another.

The health and safety of participants, staff and volunteers remain the Chapters top priority. In addition to the OSU Campus location, we will also continue to offer options to participate online and in your neighborhood, Pechlivanos said.

The Walk draws from Richland, Ashland, Knox and Crawford counties. In Northwest Ohio, 32,000 people live with the fatal progressive brain disease and 96,000 family and friends care for them.

On Walk day, participants honor those affected by Alzheimers with the poignant Promise Garden ceremony a mission-focused experience that signifies solidarity in the fight against the disease. The colors of the Promise Garden flowers represent peoples connection to Alzheimers their personal reasons to end the disease.

The Alzheimer's Association has been a huge asset to many families," Benway said. "Our journey with Alzheimer's Disease and the Association began in 2001, when my mom began to suffer with memory issues.

"Through the years of her illness we relied heavily on the local Association for education, support groups, advocacy opportunities, and so much more. When we lost my mom in 2011, after 10 years with Alzheimer's, we stepped up our game and continued to support the Alzheimer's Association, and began to raise more money and more awareness through each Walk to End Alzheimers.

"My dad continues to support and educate so many friends who now are going through the caregiving journey which he did so well. Each time I share about my mom's journey, I am reminded of how important our work is, we must find a cure.

Area residents can go to alz.org/walk to sign up as a team captain, join a team or register to walk as an individual. Participants are encouraged to download the Walk to End Alzheimers mobile app to make their experience easier. Also, the FAQ page on alz.org/walk will be updated regularly for details on the Walk-day experience.

More than 6 million Americans are living with Alzheimer's disease a leading cause of death in the United States. Additionally, more than 11 million family members and

friends provide care to people living with Alzheimers and other dementias. The Alzheimers Association Walk to End Alzheimers, which helps all affected, is the worlds largest event to raise awareness and funds for Alzheimers care, support and research.

This year has been extremely stressful for all and thats why our efforts to raise money for care and support for local families are so critical," Pechlivanos said. "This Walk to End Alzheimers will be extra special because despite the pandemic, we now have a first-ever approved treatment for Alzheimers.

"The Walk will celebrate this advancement as well as acknowledge the extraordinary efforts of caregivers this past year.

Alzheimer's Association

The Alzheimers Association is a worldwide voluntary health organization dedicated to Alzheimers care, support and research. Its mission is to lead the way to end Alzheimer's and all other dementia by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Visit alz.org or call 1-800-272-3900.

If you've ever experienced the joy of creativity and culture, then you know the value of the arts. Your support of our reporting enhances that. Become a Source member today.

View post:
Benway will chair the 2021 North Central Ohio Walk to End Alzheimer's - Richland Source

BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimers Disease at 2021 Alzheimers Association International Conference – Yahoo…

Posted: at 1:54 am


NE3107 Is the First Potentially Disease Modifying, Anti-Inflammatory Insulin Sensitizer Therapy In A Pivotal Phase 3 Trial

SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD, BioVies Executive Vice President for Neuroscience Research & Development was presented at the 2021 Alzheimers Association International Conference (AAIC).

Poster 55458 entitled Rationale for an anti-inflammatory insulin sensitizer in a phase 3 Alzheimers Disease trial highlighted the safety profile and broad mechanism of action against features of Alzheimers Disease of NE3107an oral small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds ERK. NE3017 has also been shown to selectively inhibit inflammation-driven ERK- and NFB-stimulated inflammation without inhibiting their homeostatic functions. In prior animal studies and Phase 1 and 2 human clinical trials, NE3107 has been demonstrated to be safe and effective at reducing neuroinflammation and insulin resistance, both of which are recognized as important players in Alzheimers Disease pathology.

BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study (NCT04669028). NM101 is a randomized double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate Alzheimers Disease. In addition to conventional cognition, memory, functional, behavioral and imaging end points, NM101 will assess measures of glycemic control, brain glucose utilization and systems dysregulation. The basis for this study design was recently published in a peer-reviewed article in Neurodegenerative Disease Management (https://doi.org/10.2217/nmt-2021-0022). The study is actively recruiting and screening patients and aims to have data readout by the end of 2022.

Story continues

At the AAIC this year there are literally hundreds of presentations on inflammation and Alzheimers disease and dozens on insulin resistance and AD.

NE3107 is the first potentially disease modifying, anti-inflammatory insulin sensitizer therapy in a phase 3 trial, said Cuong Do, Chief Executive Officer of BioVie. Additionally, our NM101 study is the first randomized, double blind, placebo-controlled Phase 3 trial conducted by any company to test a disease modifying anti-inflammatory insulin sensitizer therapy in subjects with mild to moderate Alzheimers. NE3107 has been shown to decrease the inflammatory signal transduction cascades that are known to inhibit insulin action in the brain, and to restore insulin action. NE3107 blocks the major inflammatory nodes of extracellular signal-regulated kinase (ERK) and nuclear factor kappa B (NFkB). In addition, examples were presented to show that NE3107 preserves both ERK and NFkB homeostatic functions. We are initiating this trial with the aim of reading out the end of 2022.

The AAIC is being held virtually and in Denver, CO, July 26-30, 2021.

About BioVie

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Companys Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal Phase 3 study of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI). BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. In neurodegenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107, that binds to ERK and selectively reduces neuroinflammation and insulin resistance. Both are drivers of Alzheimers and Parkinsons diseases. The FDA has authorized a pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimers. BioVie is planning to initiate this trial in mid-2021 and targeting primary completion in late 2022. A Phase 2 trial of NE3107 in Parkinsons Disease is planned for later this year, and related compounds have additional potential to treat certain cancers. NE3107 and related compounds are globally patented, first-in-class molecules. For more information, visit http://www.biovieinc.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical trials and to obtain approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

Contact:INVESTOR RELATIONS:Bruce MackleManaging DirectorLifeSci Advisors, LLCbmackle@lifesciadvisors.com

Go here to read the rest:
BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimers Disease at 2021 Alzheimers Association International Conference - Yahoo...

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer’s Disease – PRNewswire

Posted: at 1:54 am


WASHINGTON, July 30, 2021 /PRNewswire/ -- KeifeRx, LLC, an emerging clinical-stage biotechnology company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced today that the company received an acceptance of its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to launch a Phase 3 trial named NILEAD for Nilotinib BE.

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease. "We are very pleased thatKeifeRx'sfirst IND has been accepted by the FDA," said Charbel Moussa, MBBS, PhD, Associate Professor at Georgetown University and Co-Founder and Director of KeifeRx's Scientific Advisory Board. "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's."

"We are excited about this major milestone for KeifeRx, and the chance to demonstrate the capabilities of our tyrosine kinase inhibitors (TKI) platform in neurodegeneration," said Chris Hoyt, CEO of KeifeRx. "We are looking forward to the successful execution of this program and the ability to help people affected by such a debilitating disease."

Alzheimer's disease is a disorder that affects over 6 million people in the United States and more than 44 million people worldwide.

About NILEAD:KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease. A total of 1275 patients will be randomized into three groups (1:1:1) in which they will receive placebo or one of two doses of Nilotinib BE for 72 weeks. The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease. A biomarker sub-study will investigate the effects of Nilotinib BE on amyloid brain burden as well as other makers of Alzheimer's pathology.

About KeifeRx: KeifeRx is clinical-stage life sciences company that focuses on a family of drugs called tyrosine kinase inhibitors (TKIs) that trigger degradation of malfunctioning proteins, mitigating their pathological toxic effects. Georgetown University owns several issued patents and pending patent applications on the underlying technology that relates to the use of TKIs for treatment of neurodegenerative diseases with Charbel Moussa as an inventor. KeifeRx has an exclusive option to license to the intellectual property from Georgetown University. KeifeRx was founded in 2019 to redefine the treatment experience for patients suffering from neurodegenerative diseases and movement disorders which include but are not limited to, Alzheimer's Disease, Lewy Body Dementia and Parkinson's Disease. KeifeRx is a DMV Angels backed company.

For more information on KeifeRx, please visit https://www.keiferx.com, https://www.linkedin.com/company/keiferx, or contact: Pasha Jahangiri, 202-810-0580, [emailprotected]

KeifeRx 1356 Beverly Road, Suite 300 McLean, Virginia 22101

SOURCE KeifeRx

http://www.keiferx.com

See more here:
KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease - PRNewswire

Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline | Antibodies | News…

Posted: at 1:54 am


DetailsCategory: AntibodiesPublished on Friday, 30 July 2021 10:50Hits: 599

- P-tau217 in blood showed promise as additional biomarker of efficacy

- Donanemab treatment led to 24% lowering of P-tau217 from baseline

INDIANAPOLIS, IN, USA I July 29, 2021 I Today at the Alzheimer's Association International Conference (AAIC 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaque changes following donanemab treatment was highly associated with less cognitive decline and participants with greater plaque clearance at 24 weeks of treatment showed less tau progression. In the second, Lilly shared data showing that treatment with donanemab drives a rapid reduction of a biomarker reflecting Alzheimer's disease pathology, plasma P-tau217, which was detected within 12 weeks.

Donanemab is an investigational antibody that targets a modified form of beta amyloid plaque called N3pG. In June 2021, Lilly announced the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. No additional safety analyses were performed related to the presentations; for information on donanemab's safety profile, reference the previous publication.

"We are excited by these promising results, which provide further evidence on the potential for donanemab to slow disease progression for people with early symptomatic Alzheimer's disease," said Mark Mintun, M.D., vice president of pain and neurodegeneration, Lilly. "Importantly, these data link the mechanism of action of donanemab, plaque clearance, with positive effects on both clinical outcomes and brain tau pathology."

In the first oral presentation, donanemab induced rapid amyloid plaque reduction at 24 weeks in participants with early symptomatic AD, with the most rapid clearance in subjects with the most severe plaque burden at baseline.The subset of participants who reached complete amyloid plaque clearance at 24 weeks (defined as an amyloid level of <24.1CL)were able to stop or reduce dosing of donanemab earlier than other patients. Among those who achieved complete amyloid plaque clearance at 24 weeks and had a blinded switch to placebo, an exposure-response model showed minimal amyloid re-accumulation over the next year.

Additionally, among those who reached early complete amyloid plaque clearance status at 24 weeks, a flortaucipir positron emission tomography (PET) scan at 76 weeks showed a significant decrease of tau spread a predictive biomarker for AD progression over 76 weeks in frontal, parietal and temporal brain regions compared to placebo.

Greater amyloid plaque change at 24 weeks was also associated with improved Integrated Alzheimer's Disease Rating Scale (iADRS) score, a validated, composite measure that combines two well-established instruments used to assess cognition and daily function in AD clinical trials. Additionally, pharmacokinetic/pharmacodynamic modeling showed that greater relative amyloid plaque clearance was correlated with greater clinical benefit.

A second oral presentation focused on plasma P-tau217 (tau phosphorylated at threonine 217), a research blood-biomarker developed by Lilly, associated with amyloid and taupathology and diagnosis of Alzheimer's disease.Planned analyses showed that treatment with donanemab resulted in early reduction of P-tau217 (LS mean log10 change -0.04) and showed significant reduction (p<0.01) by the 3-month timepoint compared to placebo (LS mean log10 change 0). Decreased P-tau217 correlated significantly with amyloid change at all timepoints, at 24 weeks (R = 0.394, p<0.0001) and 76 weeks (R = 0.492, p<0.0001).

"Notably, these data support the amyloid cascade hypothesis and suggest that amyloid-related tauopathy can be altered with donanemab's impact on plaque clearance. Furthermore, the data support that early and profound amyloid clearance may translate into clinical benefit for patients," said John Sims, senior medical director of neurodegeneration and co-author of the analysis.

About DonanemabDonanemab is an investigational antibody that targets a modified form of beta amyloid plaque called N3pG. Results from a Phase 2 study of donanemab were announced and published earlier this year, and in June Lilly announced the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. Lilly plans to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year.

About TRAILBLAZER-ALZIn the TRAILBLAZER-ALZ study, donanemab dosing was 700 mg every four weeks for the first three doses, then 1400mg every four weeks, for up to 76 weeks. Planned blinded dose reduction evaluations occurred at 24 and 52 weeks.

Donanemab is also being studied in the ongoing Phase 3 TRAILBLAZER-ALZ 2 study in early, symptomatic Alzheimer's disease patients. TRAILBLAZER-ALZ 3, a prevention study, will evaluate whether treatment with donanemab can prevent the clinical progression of Alzheimer's disease in trial participants before clinical impairment begins. Visit LillyMemoryTrials.comfor additional information on enrolling in Alzheimer's disease trials.

About Alzheimer's DiseaseAlzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition. Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases.1 There are currently over 50 million people living with dementia around the world, with numbers expected to increase to nearly 152 million by 2050.2Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case every 3 seconds, and a significant increase in the caregiving burden placed on society and families.In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020.3 The current annual societal and economic cost of dementia is estimated at $1 trillion, an amount that is expected to double by 2030 unless we find a way to slow the disease.2

In an addition to age and family history of AD, the greatest risk factor for developing AD is the presence of the apolipoprotein E 4 (APOE4) allele.1 Having one APOE4 allele increases the risk of developing Alzheimer's disease by approximately three times compared with those with two copies of the APOE3 form. Those who inherit two copies of the APOE4 allele have an 8 - 12-fold risk. In addition, those with the APOE4 allele are more likely to have beta-amyloid accumulation and Alzheimer's dementia at a younger age than those with the APOE2 or APOE3 forms of the APOE gene.

AboutEli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.comand lilly.com/newsroom. P-LLY

SOURCE: Eli Lilly

Originally posted here:
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline | Antibodies | News...

Is the military researching an ‘anti-aging’ pill? – We Are The Mighty

Posted: at 1:53 am


Air Force pilots of the 1980s-era stealthy B-2 Spirit bomber plan to upgrade and fly the aircraft on attack missions against enemy air defenses well into the 2050s, service officials said.

It is a dream to fly. It is so smooth, Maj. Kent Mickelson, director of operations for 394th combat training squadron, told Scout Warrior in an interview.

In a special interview designed to offer a rare look into the technologies and elements of the B-2, Mickelson explained that the platform has held up and remained very effective given that it was designed and built during the 80s.

Alongside his current role, Mickelson is also a B-2 pilot with experience flying missions and planning stealth bomber attacks, such as the bombing missions over Libya in 2011.

It is a testament to the engineering team that here we are in 2016 and the B-2 is still able to do its job just as well today as it did in the 80s. While we look forward to modernization, nobody should come away with the thought that theB-2isnt ready to deal with the threats that are out there today, he said. It is really an awesome bombing platform and it is just a marvel of technology.

The B-2 is engineered with avionics, radar and communications technologies designed to identify and destroy enemy targets from high altitudes above hostile territory.

It is a digital airplane. We are presented with what is commonly referred to as glass cockpit, Mickelson said.

The glass cockpit includes various digital displays, including one showing Synthetic Aperture Radar (SAR) information which paints a rendering or picture of the ground below.

SAR provides the pilots with a realistic display of the ground that they are able to use for targeting, Mickelson said.

The B-2 has a two-man crew with only two ejection seats. Also, the crew is trained to deal with the rigors of a 40-hour mission.

A B-2 Spirit soars after a refueling mission over the Pacific Ocean. | U.S. Air Force photo by Staff Sgt. Bennie J. Davis III

TheB-2represents a huge leap in technology from our legacy platforms such as theB-52 and theB-1 bomber. This involved taking the best of what is available and giving it to the aircrew, Mickelson said.

The Air Force currently operates 20 B-2 bombers, with the majority of them based at Whiteman AFB in Missouri. The B-2 can reach altitudes of 50,000 feet and carry 40,000 pounds of payload, including both conventional and nuclear weapons.

The aircraft, which entered service in the 1980s, has flown missions over Iraq, Libya and Afghanistan. In fact, given its ability to fly as many as 6,000 nautical miles without need to refuel, the B-2 flew from Missouri all the way to an island off the coast of India called Diego Garcia before launching bombing missions over Afghanistan.

Taking off from Whiteman and landing at Diego Garcia was one of the longest combat sorties the B-2 has ever taken. The bomber was very successful in Afghanistan and very successful in the early parts of the wars in Iraq and Libya, Michelson added.

The B-2 crew uses whats called a long-duration kit, which includes items such as a cot for sleeping and other essentials deemed necessary for a long flight, Mickelson explained.

As a stealth bomber engineered during the height of the Cold War, the B-2 was designed to elude Soviet air defenses and strike enemy targets without an enemy ever knowing the aircraft was even there. This stealthy technological ability is referred to by industry experts as being able to evade air defenses using both high-frequency engagement radar, which can target planes, and lower frequency surveillance radar which can let enemies know an aircraft is in the vicinity.

The B-2 bomber is described as a platform which can operate undetected over enemy territory and, in effect, knock down the door by destroying enemy radar and air defenses so that other aircraft can fly through a radar corridor and attack.

However, enemy air defenses are increasingly becoming technologically advanced and more sophisticated; some emerging systems are even able to detect some stealth aircraft using systems which are better networked, using faster computer processors and able to better detect aircraft at longer distances on a greater number of frequencies. The Russian-built S-300 and S-400 air defenses, for example, are among the most advanced in the world today.

The Air Force plans to operate the B-2 alongside its new, now-in-development bomber called the Long Range Strike Bomber, or LRS-B. well into the 2050s.

U.S. Air Force photo

As a result, the B-2 fleet is undergoing a series of modernization upgrades in order to ensure the aircraft can remain at its ultimate effective capability for the next several decades, Mickelson said.

One of the key upgrades is called the Defensive Management System, a technology which helps inform the B-2 crew about the location of enemy air defenses. Therefore, if there are emerging air defenses equipped with the technology sufficient to detect the B-2, the aircraft will have occasion to maneuver in such a way as to stay outside of their range.

The Defensive Management System is slated to be operational by the mid-2020s, Mickelson added.

The whole key is to give us better situational awareness so we are able to make sound decisions in the cockpit about where we need to put the aircraft, he added.

U.S. Air Force photo

The B-2 is also moving to an extremely high frequency satellite in order to better facilitate communications with command and control. For instance, the communications upgrade could make it possible for the aircraft crew to receive bombing instructions from the President in the unlikely event of a nuclear detonation.

This program will help with nuclear and conventional communications. It will provide a very big increase in the bandwidth available for the B-2, which means an increased speed of data flow. We are excited about this upgrade, Mickelson explained.

The stealth aircraft uses a commonly deployed data link called LINK-16 and both UHF and VHF data links, as well. Michelson explained that the B-2 is capable of communicating with ground control stations, command and control headquarters and is also able to receive information from other manned and unmanned assets such as drones.

Information from nearby drones, however, would at the moment most likely need to first transmit through a ground control station. That being said, emerging technology may soon allow platforms like the B-2 to receive real-time video feeds from nearby drones in the air.

TheB-2is also being engineered with a new flight management control processor designed to expand and modernize the on-board computers and enable the addition of new software.

This involves the re-hosting of the flight management control processors, the brains of the airplane, onto much more capable integrated processing units. This results in the laying-in of some new fiber optic cable as opposed to the mix bus cable being used right now because theB-2s computers from the 80s are getting maxed out and overloaded with data, Air Force officials told Scout Warrior.

The new processor increases the performance of the avionics and on-board computer systems by about 1,000-times, he added. The overall flight management control processor effort, slated to field by 2015 and 2016, is expected to cost $542 million.

The comprehensiveB-2upgrades also include efforts to outfit the attack aircraft with next generation digital nuclear weapons such as theB-61 Mod 12 with a tail kit and Long Range Stand-Off weapon or, LRSO, an air-launched, guided nuclear cruise missile, service officials said.

U.S. Air Force photo by Master Sgt. Val Gempis

TheB-61 Mod 12 is an ongoing modernization program which seeks to integrate theB-61 Mods 3, 4, 7 and 10 into a single variant with a guided tail kit. TheB-61 Mod 12 is being engineered to rely on an inertial measurement unit for navigation.

In addition to the LRSO, B83 andB-61 Mod 12, theB-2will also carry theB-61 Mod 11, a nuclear weapon designed with penetration capabilities, Air Force officials said.

The LRSO will replace the Air Launched Cruise Missile, or ALCM, which right now is only carried by theB-52 bomber, officials said.

Alongside its nuclear arsenal, theB-2will carry a wide range of conventional weapons to include precision-guided2,000-pound Joint Direct Attack Munitions, or JDAMs, 5,000-pound JDAMs, Joint Standoff Weapons, Joint Air-to-Surface Standoff Missiles and GBU 28 5,000-pound bunker buster weapons, among others.

The platform is also preparing to integrate a long-range conventional air-to-ground standoff weapon called the JASSM-ER, for Joint Air-to-Surface Standoff Missile, Extended Range.

TheB-2can also carry a 30,000-pound conventional bomb known as the Massive Ordnance Penetrator, Mickelson added.

This is a GBU-28 (bunker-buster weapon) on steroids. It will go in and take out deeply buried targets, he said.

Go here to read the rest:
Is the military researching an 'anti-aging' pill? - We Are The Mighty

« Previous Post  Next Posts »



Page 9«..891011